| Aug 27 |
Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
|
| Aug 26 |
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
|
| Aug 9 |
Peering Into Ocugen's Recent Short Interest
|
| Aug 9 |
Q2 2024 Ocugen Inc Earnings Call
|
| Aug 8 |
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Ocugen, Inc. (OCGN) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Ocugen GAAP EPS of -$0.04 beats by $0.01, revenue of $1.14M
|
| Aug 8 |
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
|
| Aug 8 |
Ocugen: Q2 Earnings Snapshot
|
| Aug 7 |
Ocugen Q2 2024 Earnings Preview
|
